Ibiayi Dagogo‐Jack

10.0k total citations · 1 hit paper
85 papers, 4.5k citations indexed

About

Ibiayi Dagogo‐Jack is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ibiayi Dagogo‐Jack has authored 85 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in Ibiayi Dagogo‐Jack's work include Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (13 papers). Ibiayi Dagogo‐Jack is often cited by papers focused on Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (13 papers). Ibiayi Dagogo‐Jack collaborates with scholars based in United States, Australia and France. Ibiayi Dagogo‐Jack's co-authors include Alice T. Shaw, Justin F. Gainor, Jochen K. Lennerz, W. Marston Linehan, Aaron N. Hata, Satoshi Yoda, Beow Y. Yeap, Mari Mino–Kenudson, Emily Chin and Lorin A. Ferris and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Ibiayi Dagogo‐Jack

79 papers receiving 4.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour heterogeneity and resistance to cancer therapies

2017 2.4k citations Ibiayi Dagogo‐Jack, Alice T. Shaw profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ibiayi Dagogo‐Jack United States	24	2.0k	2.0k	1.9k	1.3k	446	85	4.5k
Edwin M. Posadas United States	41	2.7k 1.4×	1.9k 1.0×	1.9k 1.0×	1.9k 1.4×	611 1.4×	173	5.6k
Toru Mukohara Japan	28	1.7k 0.9×	2.3k 1.2×	1.7k 0.9×	577 0.4×	436 1.0×	128	4.1k
Steven Van Laere Belgium	45	2.6k 1.3×	2.7k 1.4×	968 0.5×	2.5k 1.8×	332 0.7×	161	5.6k
Daniel S.W. Tan Singapore	34	1.3k 0.7×	1.8k 0.9×	1.9k 1.0×	965 0.7×	197 0.4×	159	4.1k
George N. Naumov United States	22	1.9k 1.0×	2.3k 1.2×	1.3k 0.7×	1.1k 0.9×	267 0.6×	37	4.0k
Dimitris Mavroudis Greece	43	1.6k 0.8×	3.9k 2.0×	1.5k 0.8×	2.4k 1.8×	352 0.8×	107	5.2k
Alastair Greystoke United Kingdom	28	1.3k 0.6×	2.3k 1.2×	1.3k 0.7×	1.4k 1.0×	349 0.8×	144	3.8k
Ferry A.L.M. Eskens Netherlands	43	2.6k 1.3×	2.9k 1.5×	1.5k 0.8×	1.2k 0.9×	252 0.6×	161	6.4k
Hilary Calvert United Kingdom	31	2.2k 1.1×	2.6k 1.3×	1.5k 0.8×	610 0.5×	319 0.7×	79	5.0k
Niki Karachaliou Spain	39	2.7k 1.4×	2.9k 1.5×	2.7k 1.4×	1.6k 1.2×	162 0.4×	183	5.6k

Countries citing papers authored by Ibiayi Dagogo‐Jack

Since Specialization

Citations

This map shows the geographic impact of Ibiayi Dagogo‐Jack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibiayi Dagogo‐Jack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibiayi Dagogo‐Jack more than expected).

Fields of papers citing papers by Ibiayi Dagogo‐Jack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ibiayi Dagogo‐Jack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibiayi Dagogo‐Jack. The network helps show where Ibiayi Dagogo‐Jack may publish in the future.

Co-authorship network of co-authors of Ibiayi Dagogo‐Jack

This figure shows the co-authorship network connecting the top 25 collaborators of Ibiayi Dagogo‐Jack. A scholar is included among the top collaborators of Ibiayi Dagogo‐Jack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibiayi Dagogo‐Jack. Ibiayi Dagogo‐Jack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kindler, Hedy L., Ibiayi Dagogo‐Jack, Marc de Perrot, et al.. (2025). Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncology Practice. 21(10). 1413–1416.

Dagogo‐Jack, Ibiayi, Alissa J. Cooper, Justin F. Gainor, et al.. (2024). Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Lung Cancer. 199. 108003–108003. 1 indexed citations

Solomon, Benjamin, Ibiayi Dagogo‐Jack, Se-Hoon Lee, et al.. (2024). Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial. JTO Clinical and Research Reports. 5(7). 100685–100685. 1 indexed citations

Waliany, Sarah, Andrew Do, Aimin Liu, et al.. (2024). P1.12B.02 Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S199–S200. 2 indexed citations

Yap, Timothy A., Afshin Dowlati, Ibiayi Dagogo‐Jack, et al.. (2024). 1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation. European Journal of Cancer. 211. 114530–114530.

Ahn, M-J., Ibiayi Dagogo‐Jack, Francesco Gelsomino, et al.. (2024). LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1246–S1247. 2 indexed citations

Keane, Florence K., Beow Y. Yeap, Melin J. Khandekar, et al.. (2024). Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. International Journal of Radiation Oncology*Biology*Physics. 121(4). 975–979.

Riely, Gregory J., Egbert F. Smit, Myung‐Ju Ahn, et al.. (2023). Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAF^V600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.. Journal of Clinical Oncology. 41(16_suppl). 9018–9018. 1 indexed citations

Dagogo‐Jack, Ibiayi, Beow Y. Yeap, Mari Mino–Kenudson, & Subba R. Digumarthy. (2023). Extrathoracic Metastases in Pleural Mesothelioma. JTO Clinical and Research Reports. 4(9). 100557–100557. 3 indexed citations

10.

Dagogo‐Jack, Ibiayi, Philicia Moonsamy, Justin F. Gainor, et al.. (2021). A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. Journal of Thoracic Oncology. 16(5). 850–859. 40 indexed citations

11.

Dagogo‐Jack, Ibiayi & Lauren L. Ritterhouse. (2020). The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Translational Lung Cancer Research. 9(6). 2557–2570. 7 indexed citations

12.

Dagogo‐Jack, Ibiayi, Anderson H. Kuo, Dexter P. Mendoza, et al.. (2020). Clinical and Imaging Features of Non–Small-Cell Lung Cancer in Young Patients. Clinical Lung Cancer. 22(1). 23–31. 14 indexed citations

13.

Dagogo‐Jack, Ibiayi, Marguerite Rooney, W. Marston Linehan, et al.. (2019). Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research. 25(22). 6662–6670. 112 indexed citations

14.

Linehan, W. Marston, Adam J. Schoenfeld, Viola W. Zhu, et al.. (2019). Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology. 15(2). 258–265. 54 indexed citations

15.

Dagogo‐Jack, Ibiayi, Pablo Martínez, Beow Y. Yeap, et al.. (2018). Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research. 25(1). 158–165. 80 indexed citations

16.

Linehan, W. Marston, Viola W. Zhu, Adam J. Schoenfeld, et al.. (2018). Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology. 13(10). 1530–1538. 54 indexed citations

17.

Dagogo‐Jack, Ibiayi, Lecia V. Sequist, & Zofia Piotrowska. (2017). The Role of Liquid Biopsies in Lung Cancer Screening. Seminars in Roentgenology. 52(3). 185–187. 2 indexed citations

18.

Dagogo‐Jack, Ibiayi & Alice T. Shaw. (2016). Crizotinib resistance: implications for therapeutic strategies. Annals of Oncology. 27. iii42–iii50. 124 indexed citations

19.

Adamia, Sophia, Benjamin Haibe‐Kains, Patrick M. Pilarski, et al.. (2013). A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. Clinical Cancer Research. 20(5). 1135–1145. 79 indexed citations

20.

Brägelmann, Johannes, Ibiayi Dagogo‐Jack, Mohamed El Dinali, et al.. (2013). Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49(6). 525–533. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact